CLINICAL TRIAL AGREEMENT THIS AGREEMENT (this“Agreement”) is made and entered into as of the date of disclosure in the Register of Contracts (the "Effective Date") by and between Immunomedics, Inc., a Delaware corporation having a place of business at...Clinical Trial Agreement This Agreement • April 9th, 2019
ContractClinical Trial Agreement This Agreement • October 25th, 2019
CLINICAL TRIAL AGREEMENT This Agreement (hereinafter “Agreement”) is made between (1) Hexal AG Industriestrasse 25 83607 Holzkirchen Germany(Hexal) and (2) Fakultní nemocnice Plzeň Edvarda Beneše 1128/13 Jižní Předměstí305 99 PlzeňCzech RepublicCompany ID Number: 00669806 Tax ID No: CZ00669806Represented by: MUDr. Václav Šimánek, Ph.D. (dále jen zdravotnické zařízení) and (3) Václav Vyskočil PlzeňCzech Republic(Principal Investigator) SMLOUVA O KLINICKÉM HODNOCENÍ Tato smlouva (dále jen smlouva) se uzavírá mezi (1) Hexal AG Industriestrasse 25 83607 Holzkirchen Německo(dále jen Hexal) a (2) Fakultní nemocnice Plzeň Edvarda Beneše 1128/13 Jižní Předměstí305 99 Plzeň Česká republika IČO: 00669806 DIČ: CZ00669806Zastoupena: MUDr. Václav Šimánek, Ph.D. (dále jen zdravotnické zařízení) a (3) Václav Vyskočil Plzeň Česká republika(dále jen hlavní zkoušející) WHEREAS, Hexal is sponsoring a clinical trial involving subjects on ; WHEREAS, the Principal Investigator is an employee of the Institut
RÚ: 120.0088019Clinical Trial Agreement This Agreement • January 2nd, 2020
CLINICAL TRIAL AGREEMENT This Agreement (hereinafter "Agreement") is made between (1) Hexal AG lndustriestrasse 25 83607 Holzkirchen Germany (Hexal) and (2) Revmatologický ústav Na Slupi 450/4 128 00 Praha 2 - Nové Město Czech Republic Organization ID No.:00023728 Tax lD No.:CZ00023728 (the lnstitution) (the Principal lnvestigator). Institution shall appoint the Principal Investigator to take responsib1lity to conduct the Tria! and supervise the Trial Personnel on behalf of Institution. WHEREAS, the Institution shall particularly be responsible for ensuring the material conditions of the Tria!as determined in the Tria! protocol and any other written instructions that may be provided by Hexal. WHEREAS, Institution desires to participate m the Tria! as described in this Agreement. SMLOUVA O KLINICKEM HODNOCENI Tato smlouva (dálejen smlouva) se uzavírá mezi (1) Hexal AG Industriestrasse 25 83607 Holzkirchen Německo
ContractClinical Trial Agreement This Agreement • April 29th, 2019
CLINICAL TRIAL AGREEMENT THIS AGREEMENT (this“Agreement”) is made and entered into as of the date of disclosure in the Register of Contracts (the "Effective Date") by and between Immunomedics, Inc., a Delaware corporation having a place of business at 300 The American Road, Morris Plains, New Jersey 07950, tax ID: 61-1009366 (hereinafter "SPONSOR"), and Fakultní nemocnice Olomouc, with its registered office located at I.P. Pavlova 185/6, Nová Ulice, 779 00 Olomouc, IČO (Company ID): 00098892, VAT:CZ00098892, represented by Prof. Roman Havlik, M.D., Ph.D.(hereinafter “INSTITUTION”), RECITALS WHEREAS, SPONSOR conducts business in the research, development, and manufacture of biopharmaceutical products. WHEREAS, SPONSOR desires INSTITUTION to conduct a clinical trial and INSTITUTION desires to conduct same, said trial being entitled: Protocol: IMMU 132-06. A Phase II open label, study of IMMU-132 in metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1/ PD-L1 b
